English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aims/Introduction  To assess efficacy and safety of insulin degludec/liraglutide (IDegLira) in Japanese participants with type 2 diabetes across different baseline characteristics.    Materials and Methods  Data from two randomized controlled trials were used: DUAL I Japan ( n  = 819 insulin‐naïve participants) and DUAL II Japan ( n  = 210 insulin‐experienced participants). Outcomes were assessed according to baseline glycated hemoglobin ( HbA 1c ; &lt;8.0%, ≥8.0–&lt;9.0%, ≥9.0%), body mass index (&lt;25, ≥25–&lt;30, ≥30 kg/m 2 ) and age (&lt;65, ≥65 years).    Results  In DUAL I Japan, reductions in HbA 1c  with IDegLira versus degludec and liraglutide were observed across all subgroups (treatment differences: −0.48% to −0.72% vs degludec, −0.29% to −0.73% vs liraglutide). Results were similar with IDegLira versus degludec in DUAL II Japan (treatment differences: −0.82% to −1.61%). Treatment‐by‐subgroup interactions were significant for IDegLira versus liraglutide for baseline HbA 1c  and age in DUAL I Japan, and for IDegLira versus degludec for baseline HbA 1c  in DUAL II Japan. In DUAL I Japan, IDegLira was associated with less weight gain than degludec in most subgroups. In DUAL II Japan, IDegLira was associated with a small mean weight loss (except for baseline HbA 1c  ≥9.0%) versus a small gain for degludec (except for age ≥65 years subgroup); treatment‐by‐subgroup interactions were not significant. Total daily insulin dose was lower with IDegLira versus degludec across all categories, except for age &gt;65 years in DUAL II Japan.    Conclusions  IDegLira reduced HbA 1c  in Japanese participants with type 2 diabetes across baseline HbA 1c , body mass index and age categories, without unexpected safety issues.

journal of diabetes investigation

Efficacy and safety of the fixed‐ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials